Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    Researchers Closer to Countering Deadly Nipah Virus

    By Global Biodefense StaffJune 26, 2014
    Transmission electron micrograph depict Nipah virus virions that had been isolated from a patient's cerebrospinal fluid.
    Share
    Facebook LinkedIn Reddit Email
    Transmission electron micrograph depict Nipah virus virions that had been isolated from a patient’s cerebrospinal fluid.

    An interdisciplinary research team from the University of Texas Medical Branch at Galveston, the Uniformed Services University of the Health Sciences (USU) and three groups within the National Institutes of Health reports a new breakthrough in countering the deadly Nipah virus.

    The human monoclonal antibody known as m102.4 is the first effective antiviral treatment for Nipah that has the potential for human therapeutic applications.

    Nipah and the closely related Hendra virus are highly infectious agents that emerged from Pteropid fruit bats in the 1990s, causing serious disease outbreaks in a variety of domestic animals and humans in Australia, Malaysia, Singapore, Bangladesh and India. Recent Nipah outbreaks have resulted in acute respiratory distress syndrome and encephalitis, person-to-person transmission and greater than 90 percent fatality rates among people. These properties make both Nipah and Hendra viruses a concern to human and livestock health.

    Previous studies conducted by these researchers have found that the patented m102.4 antibody therapy could protect nonhuman primates from a deadly Hendra infection. In a paper appearing in Science Translational Medicine on June 25, the group describes the human monoclonal antibody therapy that protected nonhuman primates from disease at several time points after Nipah exposure, including the onset of clinical illness in this lethal disease.

    “What makes this study unique is that we have achieved complete protection against death even in animals that received treatment five days after being infected with the Nipah virus when they otherwise would have succumbed within 8-10 days of infection,” according to UTMB professor Thomas Geisbert, first author of the paper. “This recent success of the antibody therapy against Nipah virus disease in a nonhuman primate is a key step towards its development as a therapeutic for use in people.”

    Christopher Broder, USU professor and Geisbert’s fellow senior author, stated that because of the new data and previous work with this antibody with Hendra virus experiments, “there was sufficient interest for the Queensland government in Australia to initiate a phase I clinical safety trial with m102.4 that is set to commence later this year.”

    Read at Science Translational Medicine:  Therapeutic Treatment of Nipah Virus Infection in Nonhuman Primates with a Neutralizing Human Monoclonal Antibody.

    Source: University of Texas Medical Branch at Galveston

    Antivirals Nipah Virus
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleUSAMRIID Leads Effort on Viral Genome Sequencing Standards
    Next Article OSU Develops Blood-Cleaning Device to Treat Sepsis

    Related Stories

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023

    Call for Experts: Smallpox Medical Countermeasures

    October 28, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.